SG11202011369VA - Blood biomarkers of stroke - Google Patents

Blood biomarkers of stroke

Info

Publication number
SG11202011369VA
SG11202011369VA SG11202011369VA SG11202011369VA SG11202011369VA SG 11202011369V A SG11202011369V A SG 11202011369VA SG 11202011369V A SG11202011369V A SG 11202011369VA SG 11202011369V A SG11202011369V A SG 11202011369VA SG 11202011369V A SG11202011369V A SG 11202011369VA
Authority
SG
Singapore
Prior art keywords
stroke
blood biomarkers
biomarkers
blood
Prior art date
Application number
SG11202011369VA
Inventor
Serge Timsit
Emmanuelle Genin
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Francais Du Sang Ets
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Francais Du Sang Ets, Inst Nat Sante Rech Med, Univ Bretagne Occidentale filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of SG11202011369VA publication Critical patent/SG11202011369VA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202011369VA 2018-05-16 2019-05-16 Blood biomarkers of stroke SG11202011369VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16
PCT/EP2019/062653 WO2019219831A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Publications (1)

Publication Number Publication Date
SG11202011369VA true SG11202011369VA (en) 2020-12-30

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011369VA SG11202011369VA (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Country Status (12)

Country Link
US (1) US20210214793A1 (en)
EP (1) EP3794355A1 (en)
JP (1) JP7463351B2 (en)
KR (1) KR20210049026A (en)
CN (1) CN112424609A (en)
AU (1) AU2019270404A1 (en)
BR (1) BR112020023259A2 (en)
CA (1) CA3100171A1 (en)
MA (1) MA52617A (en)
MX (1) MX2020012297A (en)
SG (1) SG11202011369VA (en)
WO (1) WO2019219831A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154398A1 (en) * 2019-01-22 2020-07-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (en) * 2021-12-23 2024-01-09 太原市精神病医院 Product for diagnosing cerebral apoplexy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO2003008647A2 (en) * 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) * 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
WO2014120731A1 (en) 2013-02-01 2014-08-07 West Virginia University A biomarker algorithm for determining the time of stroke symptom onset and method
WO2015054700A2 (en) * 2013-10-13 2015-04-16 The Research Foundation For Suny Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CA2992139A1 (en) * 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
WO2018067571A2 (en) * 2016-10-03 2018-04-12 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Also Published As

Publication number Publication date
JP2021523744A (en) 2021-09-09
CA3100171A1 (en) 2019-11-21
JP7463351B2 (en) 2024-04-08
CN112424609A (en) 2021-02-26
BR112020023259A2 (en) 2021-02-23
US20210214793A1 (en) 2021-07-15
AU2019270404A1 (en) 2020-12-10
MA52617A (en) 2021-03-24
WO2019219831A1 (en) 2019-11-21
EP3794355A1 (en) 2021-03-24
KR20210049026A (en) 2021-05-04
MX2020012297A (en) 2021-03-25
AU2019270404A2 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
IL268731A (en) New uses of anti-sirpg antibodies
GB201719639D0 (en) Setection of biomarkers
IL262623B2 (en) Tourniquet
SG11202011369VA (en) Blood biomarkers of stroke
IL268187A (en) Use of senicapoc for treatment of stroke
EP3635402A4 (en) Biomarker of disease
IL276107A (en) Solid forms of fasoracetam
EP3794361C0 (en) State analysis of an inductive operating resource
SG11202105136WA (en) Application of chidamide
GB2579122B (en) Tissue analysis
GB201721723D0 (en) Biomarkers of impaired health
IL281882A (en) Microdosing
AU2018903745A0 (en) Biomarkers of disease
GB201811451D0 (en) Blood analysis
AU2017905180A0 (en) Biomarker of disease
CA190045S (en) Portion of an insole
CA189475S (en) Portion of an insole
GB201808489D0 (en) Novel biomarkers
GB201808400D0 (en) Novel biomarkers
AU2017901921A0 (en) Biomarker of disease
GB201809872D0 (en) Biomarkers
GB201809868D0 (en) Biomarkers
GB201809854D0 (en) Biomarkers
GB201809882D0 (en) Biomarkers
GB201809885D0 (en) Biomarkers